Source comparison
BPC-157 Administration Routes: Clinical Application Comparison
Subcutaneous injection ~95% systemic absorption Tendon injuries, joint inflammation, systemic tissue repair 24–48 hours for subjective pain reduction Requires patient training on sterile injection technique; injection site rotation essential to prevent lipohyp
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- ~95% systemic absorption
- Tendon injuries, joint inflammation, systemic tissue repair
- 24–48 hours for subjective pain reduction
- Requires patient training on sterile injection technique; injection site rotation essential to prevent lipohypertrophy
- Most reliable for consistent plasma levels; preferred for acute injuries and conditions requiring rapid systemic distribution
- Oral (gastric-resistant capsule)
- 15–25% systemic absorption
- Gastrointestinal mucosal healing, IBD symptoms, oral tolerance induction
- 3–7 days for GI symptom improvement
- Higher total dose required; take 30 minutes before meals on empty stomach
- Best for GI-focused protocols where local mucosal exposure is primary goal; less effective for systemic conditions
- Intramuscular injection
- ~90% systemic absorption
- Deep tissue injuries, muscle tears, localised inflammation
- 48–72 hours
- Injection site pain more common than subcutaneous; requires deeper needle penetration
- Offers no bioavailability advantage over subcutaneous; subcutaneous is generally preferred due to ease of administration
- Topical (experimental)
- <5% transdermal penetration
- Surface wounds, minor abrasions only
- Variable; limited evidence
- Peptide molecular weight (1,419 Da) exceeds optimal transdermal absorption range (~500 Da)
- Not recommended for therapeutic use. Transdermal penetration insufficient to achieve systemic or deep tissue concentrations